Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1481-1483

  Malet, Isabelle ^a   Wirden, Marc ^a   Fourati, Slim ^a   Armenia, Daniele ^b   Masquelier, Bernard ^c   Fabeni, Lavinia ^b,d   Sayon, Sophie ^a   Katlama, Christine ^a   Perno, Carlo Federico ^b,d   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a   Ceccherini Silberstein, Francesca ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Failure; Polymorphism; Prevalence

Indexed keywords

GSK1349572; INTEGRASE; INTEGRASE INHIBITOR; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG TREATMENT FAILURE; GENE MUTATION; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PREVALENCE;

AMINO ACID SUBSTITUTION; ANTHRACENES; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MUTATION, MISSENSE; PREVALENCE; PYRROLIDINONES; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS;

EID: 79958857289     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr152     Document Type: Article

References (9)

1. Grinsztejn B, Nguyen BY, Katlama C et al. Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 1261-9.
2. Sato A, Kobayashi M, Yoshinaga T et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor. In: Abstracts of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract WEPEA097.
3. Seki T, Kobayashi M, Wakasa-Morimoto C et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 555. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
4. Sato A, Seki T, Kobayashi M et al. In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/GSK1349572. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract H-932. American Society for Microbiology, Washington, DC, USA.
5. Lalezari J, Sloan L, Dejesus E et al. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-naïve HIV-1-infected patients. In: Abstracts of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract TUAB105.
6. Eron J, Durant J, Poizot-Martin I et al. Activity of next generation integrase inhibitor (INI) S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract MOAB0105.
7. Ceccherini-Silberstein F, Malet I, D'Arrigo R et al. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11: 17-29.
8. Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52: 1351-8.
9. Vavro C, Underwood M, Madsen H et al. Polymorphisms at position 101 and 124 in the HIV-1 integrase (IN) gene: lack of effects on susceptibility to S/GSK1349572. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract H-935. American Society for Microbiology, Washington, DC, USA.